Aesthetics Product Guide

Live Cosmetic Breast Surgeries to Train Doctors at KEM Hospital

Jim Marino — Mon, 26 Jul 2010 04:57:22 +0000

With an increasing number of women getting cosmetic breast surgeries done at civic hospitals in Mumbai, Parel’s KEM Hospital is holding a day-long workshop on ‘aesthetic breast surgery’ for its doctors. Experts will conduct four live breast surgeries to offer exposure to post-graduate medical students and about 70 other plastic surgeons from across the country. The four live surgeries which will be conducted as part of the workshop.

Read the full story here

European Medicines Agency Confirms Positive Benefit-Risk Balance Of Topical Formulations Of Ketoprofen

Jim Marino — Mon, 26 Jul 2010 04:53:49 +0000

Following a review of topical formulations of ketoprofen, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefit-risk balance of these medicines continues to be positive. However, the Committee recommended that doctors should inform patients on how to use these medicines appropriately. Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID). Topical formulations of ketoprofen are used to treat minor trauma, tendonitis, small-joint osteoarthritis, acute low-back pain and phlebitis.

Read the full story here

AmStem Reports Positive Early Results From SteMixxTM Consumer Study

Jim Marino — Mon, 19 Jul 2010 09:12:43 +0000

AmStem Corporation announced positive early results from its preliminary consumer study of SteMixx™. Full study results will be available at the end of this month. AmStem has engaged a labeling consultant for their flagship SteMixx™ product to make it available for retail consumer use as soon as possible in the U.S. AmStem has finalized its submission to an independent Institutional Review Board (IRB) to begin the first clinical trial of SteMixx in the United States.

Read the full story here

Nitric BioTherapeutics Initiates Phase II Onychomycosis Study

Jim Marino — Mon, 19 Jul 2010 09:08:42 +0000

Nitric BioTherapeutics, Inc. announced the initiation of a Phase II clinical trial of the company’s proprietary drug/device combination, which delivers terbinafine via the process of iontophoresis for the treatment of onychomycosis. Onychomycosis is commonly known as toenail fungus. Nitric Bio’s proprietary drug/device combination delivers very high doses of a unique formulation of terbinafine, the most effective medication used to treat onychomycosis, directly to the site of the infection – on, around and under the toenail.

Read the full story here

Opt For Breast Augmentation Surgery To Correct Uneven Breasts

Jim Marino — Fri, 16 Jul 2010 19:03:44 +0000

Women seek breast augmentation surgery for a variety of reasons–for a fuller figure, for a more youthful breast shape, and sometimes to even out the size of their breasts. Uneven breasts are fairly normal. In fact most women have one breast that is at least slightly larger than the other. However, for women with noticeably uneven breasts, breast augmentation surgery can be a great solution for bringing them into balance.

Read the full story here.

Advantages Of Dermal fillers Outweigh The Risks

Jim Marino — Fri, 16 Jul 2010 18:54:23 +0000

Dermal fillers are often confused with Botox, and though both are delivered by injection, they serve very different purposes. As the name implies, fillers are designed to plump wrinkles, fill in hollowness and enhance lips, while Botox targets and relaxes muscles to prevent new lines from developing. The advantages of fillers outweigh the risks, according to experts such as Dr. Neal Schultz of DermTV.com. Fillers are generally cost-effective (starting at a few hundred dollars), easy to administer and natural looking. Schultz says. The effects generally last four to 12 months. The risks? Fillers can cause occasional bruising, mild pain or discomfort when injected and, in rare circumstances, allergic reactions.

Read the full story here.

FDA Approves Adapalene Cream for Acne Vulgaris

Jim Marino — Wed, 07 Jul 2010 19:00:30 +0000

E. Fougera & Co has received first generic approval from the FDA for Adapalene Cream 0.1% (Rx) for the treatment of acne vulgaris. Fougera’s Adapalene Cream 0.1% is rated AB, generically equivalent to Differin® by Galderma Pharmaceuticals. According to industry data, U.S. sales of the brand named product in 2009 exceeded $55 million. This approval also marks the fourth product approval that the FDA has granted to Fougera this year.

Mesynthes Introduces Tissue Substitute

Jim Marino — Wed, 07 Jul 2010 18:56:26 +0000

Mesynthes has introduced a tissue substitute for people suffering from tissue damage, burns and reconstructive surgeries. The company’s Endoform Dermal Template is an FDA approved ready-to-use tissue substitute that can be used for wound care and dermal reconstruction. The product will improve the rate and quality of healing. Mesynthes is also developing Endoform Infection Control for the prevention of infection if there is a high risk of post-operative infection.

DUSA Pharma says USPTO upholds key photodynamic therapy patent

Jim Marino — Mon, 28 Jun 2010 14:32:11 +0000

DUSA Pharmaceuticals, Inc. has announced that the United States Patent and Trademark Office (USPTO) has completed its re-examination of US Patent No. 5,079,262, “Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid.” In its latest communication, the USPTO issued a Notice of Intent to Issue Ex Parte Re-examination Certificate which affirms the patent’s original seven claims and adds eight claims.

Read the full story here

European CHMP Concludes Re-examination Of Ceftobiprole

Jim Marino — Mon, 28 Jun 2010 14:29:36 +0000

Basilea Pharmaceutica Ltd. announces that following a request for re-examination from the Applicant Janssen-Cilag International NV (Janssen-Cilag), a Johnson & Johnson company, the European Committee for Medicinal Products for Human Use (CHMP) confirmed its previous negative opinion on the Marketing Authorization Application (MAA) for ceftobiprole for the treatment of complicated skin and soft tissue infections (cSSTI). The CHMP has confirmed its previous negative opinion on the use of ceftobiprole for the treatment of cSSTI.

Read the full story here